These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11354393)

  • 1. Can placebo controls reduce the number of nonresponders in clinical trials? A power-analytic perspective.
    Leon AC
    Clin Ther; 2001 Apr; 23(4):596-603. PubMed ID: 11354393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward rapproachment in the placebo control debate. A calculated compromise of power.
    Leon AC; Solomon DA
    Eval Health Prof; 2003 Dec; 26(4):404-14. PubMed ID: 14631611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot seminar on ethical issues in clinical trials for cancer researchers in Vietnam.
    Love RR; Fost N
    IRB; 2003; 25(6):8-10. PubMed ID: 15035249
    [No Abstract]   [Full Text] [Related]  

  • 4. The mousetrap: managing the placebo effect in antidepressant trials.
    Lakoff A
    Mol Interv; 2002 Apr; 2(2):72-6. PubMed ID: 14993352
    [No Abstract]   [Full Text] [Related]  

  • 5. The placebo response in clinical trials-the current state of play.
    Enck P; Klosterhalfen S
    Complement Ther Med; 2013 Apr; 21(2):98-101. PubMed ID: 23497810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative designs of controlled clinical trials in epilepsy.
    Gram L; Schmidt D
    Epilepsia; 1993; 34 Suppl 7():S1-6. PubMed ID: 8243373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.
    Ellenberg SS; Temple R
    Ann Intern Med; 2000 Sep; 133(6):464-70. PubMed ID: 10975965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo response and antidepressant clinical trial outcome.
    Khan A; Detke M; Khan SR; Mallinckrodt C
    J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are placebo-controlled trials still important for obsessive compulsive disorder?
    Fineberg NA; Hawley CJ; Gale TM
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):413-22. PubMed ID: 16413647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-placebo difference: in antidepressant drug trials could be 50% greater than previously believed.
    Rihmer Z
    Neuropsychopharmacol Hung; 2007 Mar; 9(1):35-7. PubMed ID: 17879563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovation and placebos in research: a new design of clinical trial.
    Holbrook A; Goldsmith C
    Lancet; 2003 Dec; 362(9401):2036-7. PubMed ID: 14697799
    [No Abstract]   [Full Text] [Related]  

  • 12. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials of investigational antiepileptic drugs: monotherapy designs.
    Pledger GW; Kramer LD
    Epilepsia; 1991; 32(5):716-21. PubMed ID: 1915182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials.
    Glasser SP; Clark PI; Lipicky RJ; Hubbard JM; Yusuf S
    JAMA; 1991 Mar; 265(12):1550-4. PubMed ID: 1671885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
    D'Agostino RB; Massaro JM; Sullivan LM
    Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of the placebo lead-in design for clinical trials with binary outcomes.
    Homma G; Daimon T
    Clin Trials; 2023 Apr; 20(2):145-152. PubMed ID: 36627841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebos: our most effective therapy?
    Holbrook A; Goldsmith C
    Can J Clin Pharmacol; 2004; 11(1):e39-40. PubMed ID: 15226525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo--efficacy and adverse effects in controlled clinical trials.
    Weihrauch TR; Gauler TC
    Arzneimittelforschung; 1999 May; 49(5):385-93. PubMed ID: 10367099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debate about placebos points to issue surrounded by many shades of grey.
    Baer N
    CMAJ; 1996 Nov; 155(10):1475-6. PubMed ID: 8943938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.